Cancer gene therapy with conditionally replicating adenoviruses is a powerful way of overcoming low tumor transduction. However, one of the main remaining obstacles is the highly variable level of the coxsackie-adenovirus receptor expression on human primary cancers. In contrast, the epidermal growth factor receptor (EGFR) is overexpressed in various tumor types, and its expression correlates with metastatic behavior and poor prognosis. We constructed an adenovirus expressing a secretory adaptor capable of retargeting adenovirus to EGFR, resulting in a more than 150-fold increase in gene transfer. A replication-competent dual-virus system secreting the adaptor displayed increased oncolytic potency in vitro and therapeutic gain in vivo. This approach could translate into increased efficacy and specificity in the treatment of EGFR overexpressing human cancers.

Original languageEnglish
Pages (from-to)6377-6381
Number of pages5
JournalCancer research
Issue number17
StatePublished - Aug 1 2001


Dive into the research topics of 'Targeting oncolytic adenoviral agents to the epidermal growth factor pathway with a secretory fusion molecule'. Together they form a unique fingerprint.

Cite this